Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Genmab A/S

GMABNASDAQ
Healthcare
Biotechnology
$29.19
$0.29(1.003%)
U.S. Market is Open • 12:28

Genmab A/S (GMAB) Stock Overview

Explore Genmab A/S’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap18B
P/E Ratio17.44
EPS (TTM)$2.26
ROE0.24%
Fundamental Analysis

AI Price Forecasts

1 Month$25.46
3 Months$39.91
1 Year Target$31.89

GMAB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Genmab A/S (GMAB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 36.30, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $31.89.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.44 and a market capitalization of 18B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.35%
5-Day Change
-1.21%
1-Month Change
-6.51%
3-Month Change
-2.50%
6-Month Change
21.74%
Year-to-Date (YTD) Change
-7.95%
1-Year Change
30.53%
3-Year Change
-25.39%
5-Year Change
-23.42%
All-Time (Max) Change
676.92%

Contact Information

45 70 20 27 28
Kalvebod Brygge 43, Copenhagen, NaN, 1560

Company Facts

26,380 Employees
IPO DateJun 1, 2009
CountryDK
Actively Trading

Frequently Asked Questions